Time-to-treatment of diffuse large B-cell lymphoma in São Paulo (2014)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- DOI: 10.6061/clinics/2014(05)12
- Subjects: LINFOMA; PROGNÓSTICO; LINFÓCITOS B; SAÚDE PÚBLICA; DIAGNÓSTICO
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
XAVIER, Flávia Dias; LEVY, Debora; PEREIRA, Juliana. Time-to-treatment of diffuse large B-cell lymphoma in São Paulo. Clinics, São Paulo, v. 69, n. 5, p. 367-371, 2014. Disponível em: < http://www.scielo.br/pdf/clin/v69n5/1807-5932-clin-69-05-367.pdf > DOI: 10.6061/clinics/2014(05)12. -
APA
Xavier, F. D., Levy, D., & Pereira, J. (2014). Time-to-treatment of diffuse large B-cell lymphoma in São Paulo. Clinics, 69( 5), 367-371. doi:10.6061/clinics/2014(05)12 -
NLM
Xavier FD, Levy D, Pereira J. Time-to-treatment of diffuse large B-cell lymphoma in São Paulo [Internet]. Clinics. 2014 ; 69( 5): 367-371.Available from: http://www.scielo.br/pdf/clin/v69n5/1807-5932-clin-69-05-367.pdf -
Vancouver
Xavier FD, Levy D, Pereira J. Time-to-treatment of diffuse large B-cell lymphoma in São Paulo [Internet]. Clinics. 2014 ; 69( 5): 367-371.Available from: http://www.scielo.br/pdf/clin/v69n5/1807-5932-clin-69-05-367.pdf - CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)
- Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
- Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings
- 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- A difficult case of angioimmunoblastic T-cell lymphoma to diagnose
- Estudo de células precuroras em leucemias agudas: identificação e fator de prognóstico das proteínas Bcl-2, Bax e CD95/Fas/APO-1
- Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study
Informações sobre o DOI: 10.6061/clinics/2014(05)12 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
